Document Detail


Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis.
MedLine Citation:
PMID:  23277789     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Biopharmaceuticals are drugs which are based on naturally occurring proteins (antibodies, receptors, cytokines, enzymes, toxins), nucleic acids (DNA, RNA) or attenuated microorganisms. Immunogenicity of these agents has been commonly described and refers to a specific antidrug antibody response. Such immunogenicity represents a major factor impairing the efficacy of biopharmaceuticals due to biopharmaceutical neutralization. Indeed, clinical experience has shown that induction of antidrug antibodies is associated with a loss of response to biopharmaceuticals and also with hypersensitivity reactions. The first disease-specific agent licensed to treat multiple sclerosis (MS) was interferon-β (IFNβ). In its various preparations, it remains the most commonly used first-line agent. The occurrence of antidrug antibodies has been extensively researched in MS, particularly in relation to IFNβ. However, much controversy remains regarding the significance of these antibodies and incorporation of testing into clinical practice. Between 2% and 45% of people treated with IFNβ will develop neutralizing antibodies, and this is dependent on the specific drug and dosing regimen. The aim of this review is to discuss the use of IFNβ in MS, the biological and clinical relevance of anti-IFNβ antibodies (binding and neutralizing antibodies), the incorporation of testing in clinical practice and ongoing research in the field.
Authors:
Paul I Creeke; Rachel A Farrell
Related Documents :
1772649 - Normal human serum depleted of c1q, factor d and properdin: its use in studies of compl...
14112269 - Pepsin digestion of rabbit and sheep antibodies. the effect on complement fixation.
19038459 - Characteristics of fc-independent human antimannan antibody-mediated alternative pathwa...
1702139 - Intersection of the complement and immune systems: a signal transduction complex of the...
2967579 - A rapid micro-method for the study of antibody-mediated killing of bacteria, with speci...
22085019 - A screening assay to identify agents that enhance t-cell recognition of human melanomas.
469269 - A new method for measuring antibody using radiolabeled protein a1 in a solid-phase radi...
18537029 - Study on molecular interactions between proteins on live cell membranes using quantum d...
11779169 - In vitro self-assembled hcv core virus-like particles induce a strong antibody immune r...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Therapeutic advances in neurological disorders     Volume:  6     ISSN:  1756-2856     ISO Abbreviation:  Ther Adv Neurol Disord     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-01-02     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101480242     Medline TA:  Ther Adv Neurol Disord     Country:  England    
Other Details:
Languages:  eng     Pagination:  3-17     Citation Subset:  -    
Affiliation:
Blizard Institute, Queen Mary University London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Structural neuroimaging of concomitant depressive symptoms in amnestic mild cognitive impairment: a ...
Next Document:  Current and future treatments for Alzheimer's disease.